EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Sacubitril/Valsartan and elevated prothrombin time/international normalized ratio in the absence of anticoagulant therapy: a newly recognized potential adverse drug reaction

Tanuj Diyora, Ayush Ranajn

European Journal of Case Reports in Internal Medicine · 03.06.2026 · 13 (6)

DOI: 10.12890/2026_006801 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Case Reports in Internal Medicine, online erschienen am 03.06.2026. Verfasst von Tanuj Diyora und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Dr KNS Memorial Institute of Medical Sciences, Barabanki, India. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Sacubitril/valsartan is the first approved angiotensin receptor–neprilysin inhibitor (ARNI) and a cornerstone therapy for heart failure with reduced ejection fraction (HFrEF). While its clinical benefits are well established, adverse drug reactions (ADRs) beyond the recognized profile of hypotension, hyperkalaemia, and renal impairment remain incompletely characterized. Case description: We report a case of isolated elevation in prothrombin time (PT) and international normalized ratio (INR) in a 58-year-old male with HFrEF receiving sacubitril/valsartan 49/51 mg twice daily, without any concurrent anticoagulant therapy. Approximately 6 weeks after initiation, PT was 18.4 seconds and INR was 1.7. Temporary discontinuation (dechallenge) led to normalization within 2 weeks; cautious re-challenge resulted in recurrent INR elevation. Naranjo Adverse Drug Reaction Probability Scale criteria yielded a score of +9, consistent with a probable drug-induced adverse event.

Conclusion

This case highlights a potentially underrecognized coagulopathic ADR associated with sacubitril/valsartan, manifesting as elevated PT/INR without anticoagulant use. Clinicians should consider periodic coagulation monitoring in patients on ARNI therapy. Further pharmacovigilance studies and mechanistic investigations are strongly warranted.

Schlagwörter

Stichwörter der Autor:innen

INRSacubitril/valsartanadverse drug reactionheart failureprothrombin time

Autor:innen und Institutionen

  • Department of Cardiology, Dr KNS Memorial Institute of Medical Sciences, Barabanki, India.
  • Department of Cardiology, Health City Vistar Hospital, Lucknow, India.

Zitieren

APA

Diyora, T., & Ranajn, A. (2026). Sacubitril/Valsartan and elevated prothrombin time/international normalized ratio in the absence of anticoagulant therapy: a newly recognized potential adverse drug reaction. European Journal of Case Reports in Internal Medicine, 13(6). https://doi.org/10.12890/2026_006801

Vancouver

Diyora T, Ranajn A. Sacubitril/Valsartan and elevated prothrombin time/international normalized ratio in the absence of anticoagulant therapy: a newly recognized potential adverse drug reaction. European Journal of Case Reports in Internal Medicine. 2026;13(6). doi:10.12890/2026_006801

BibTeX
@article{Diyora2026,
  author = {Diyora, Tanuj and Ranajn, Ayush},
  title = {Sacubitril/Valsartan and elevated prothrombin time/international normalized ratio in the absence of anticoagulant therapy: a newly recognized potential adverse drug reaction},
  journal = {European Journal of Case Reports in Internal Medicine},
  year = {2026},
  volume = {13},
  number = {6},
  doi = {10.12890/2026_006801}
}
Kostenlos starten →